Athersys, Inc. (NASDAQ:ATHX) has been assigned a $12.00 price target by equities researchers at Maxim Group in a report issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Monday, August 14th. ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $7.17.

Athersys (NASDAQ ATHX) opened at $1.78 on Thursday. Athersys has a twelve month low of $1.02 and a twelve month high of $2.63.

TRADEMARK VIOLATION WARNING: “Athersys, Inc. (ATHX) Given a $12.00 Price Target at Maxim Group” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at

In other Athersys news, insider William Lehmann, Jr. sold 15,000 shares of Athersys stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $2.38, for a total transaction of $35,700.00. Following the completion of the sale, the insider now directly owns 527,380 shares of the company’s stock, valued at approximately $1,255,164.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ATHX. Vanguard Group Inc. raised its holdings in shares of Athersys by 19.5% during the 1st quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after purchasing an additional 637,322 shares in the last quarter. Mckinley Capital Management LLC Delaware bought a new stake in shares of Athersys during the third quarter valued at about $1,093,000. Royal Bank of Canada increased its position in shares of Athersys by 7,334.0% in the second quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 375,723 shares during the last quarter. Perkins Capital Management Inc. purchased a new stake in Athersys in the third quarter worth approximately $636,000. Finally, State Street Corp increased its holdings in shares of Athersys by 27.2% during the second quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after acquiring an additional 305,944 shares in the last quarter. Institutional investors and hedge funds own 19.33% of the company’s stock.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.